ZURICH, Nov 12 (Reuters) - Biogen Idec Inc. (BIIB.O: Quote, Profile, Research) sees no logic in a potential tie-up with the Swiss-based biotech firm Serono SA (SEO.VX: Quote, Profile, Research) , which last week said it had hired investment bankers to explore its strategic options. The chief executive of the U.S. maker of multiple sclerosis treatments told the Finanz und Wirtschaft newspaper in an interview published on Saturday that he saw no sense in a deal.
